Search Results - "Schino, Pietro"
-
1
Fibrotic outcomes from SARS-CoV-2 virus interstitial pneumonia
Published in Monaldi archives for chest disease (16-10-2024)“…Following the onset of the new COVID-19 pandemic, particular attention is paid to the long-term outcomes, especially concerning patients affected by the…”
Get full text
Journal Article -
2
ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study
Published in Respiratory research (19-02-2022)“…Data from phase 3 trials have demonstrated the efficacy and safety of benralizumab in patients with severe eosinophilic asthma (SEA). We conducted a real-world…”
Get full text
Journal Article -
3
Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study
Published in Respiratory research (20-05-2023)“…The efficacy of benralizumab has been broadly demonstrated in severe eosinophilic asthma (SEA), but only few real-life studies evaluated its long-term effects…”
Get full text
Journal Article -
4
Circadian rhythm of COPD symptoms in clinically based phenotypes. Results from the STORICO Italian observational study
Published in BMC pulmonary medicine (09-09-2019)“…Chronic Obstructive Pulmonary Disease (COPD) encompasses various phenotypes that severely limit the applicability of precision respiratory medicine. The…”
Get full text
Journal Article -
5
Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis
Published in Frontiers in allergy (18-05-2022)“…Background Severe eosinophilic asthma (SEA) in the presence of chronic rhinosinusitis with nasal polyps (CRSwNP) indicates the presence of a more extensive…”
Get full text
Journal Article -
6
Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis
Published in Frontiers in medicine (02-09-2022)“…Background Severe asthma is a heterogeneous inflammatory disease driven by eosinophilic inflammation in the majority of cases. Despite biologic therapy…”
Get full text
Journal Article -
7
Correction to: Circadian rhythm of COPD symptoms in clinically based phenotypes. Results from the STORICO Italian observational study
Published in BMC pulmonary medicine (04-12-2019)“…Following publication of the original article [1], the authors flagged that the article had been provided with the names of the authors (not including the…”
Get full text
Journal Article -
8
TRITRIAL: The Impact of Fixed Triple Therapy with Beclometasone/Formoterol/Glycopyrronium on Health Status and Adherence in Chronic Obstructive Pulmonary Disease in an Italian Context of Real Life
Published in International journal of chronic obstructive pulmonary disease (01-01-2024)“…The TRITRIAL study assessed the effects of beclometasone dipropionate/formoterol fumarate/glycopyrronium (BDP/FF/G) fixed combination in patients with chronic…”
Get full text
Journal Article -
9
Quality standards for the management of bronchiectasis in Italy: a national audit
Published in The European respiratory journal (01-07-2016)“…Although historically considered a neglected disease, bronchiectasis has become a disease of renewed interest over recent decades in light of an increase in…”
Get full text
Journal Article -
10
Sustained Effectiveness of Benralizumab in Naive and Biologies-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study
Published in Journal of asthma and allergy (31-03-2024)“…Purpose: Severe eosinophilic asthma (SEA) patients often present overlapping inflammatory features rendering them eligible for multiple biologic therapies;…”
Get full text
Journal Article -
11
Adherence to GOLD guidelines in real-life COPD management in the Puglia region of Italy
Published in International journal of chronic obstructive pulmonary disease (01-01-2018)“…COPD is a disease associated with significant economic burden. It was reported that Global initiative for chronic Obstructive Lung Disease (GOLD)…”
Get full text
Journal Article -
12
The “Traffic Light OSA-SARS”: a tool for the management of obstructive sleep apnea in the pandemic era
Published in Journal of clinical sleep medicine (01-11-2021)Get full text
Journal Article -
13
Clinical Evolution and Quality of Life in Clinically Based COPD Chronic Bronchitic and Emphysematous Phenotypes: Results from the 1-Year Follow-Up of the STORICO Italian Observational Study
Published in International journal of chronic obstructive pulmonary disease (31-07-2021)“…Introduction: Understanding clinical evolution of chronic obstructive pulmonary disease (COPD) is crucial for improving disease management. Materials and…”
Get full text
Journal Article -
14
Pharmacological approach and adherence to treatment recommendations in frequently and non-frequently exacerbating COPD patients from Italy: MISTRAL - The prospective cohort, observational study
Published in Pulmonary pharmacology & therapeutics (01-12-2018)“…Several documents and guidelines provide recommendations for effective management of COPD patients. However, there is often a significant imbalance between…”
Get full text
Journal Article -
15
Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study
Published in Journal of asthma and allergy (01-01-2024)“…Severe eosinophilic asthma (SEA) patients often present overlapping inflammatory features rendering them eligible for multiple biologic therapies; switching…”
Get full text
Journal Article -
16
Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm : A Post Hoc Analysis from the ANANKE Study
Published in Journal of asthma and allergy (30-11-2022)“…Purpose: Benralizumab effectively reduces severe eosinophilic asthma (SEA) exacerbations in patients with a wide range of baseline blood eosinophil count…”
Get full text
Journal Article -
17
Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm 3 : A Post Hoc Analysis from the ANANKE Study
Published in Journal of asthma and allergy (2022)“…Benralizumab effectively reduces severe eosinophilic asthma (SEA) exacerbations in patients with a wide range of baseline blood eosinophil count (BEC)…”
Get full text
Journal Article -
18
Utility of FVC/DLCO ratio to stratify the risk of mortality in unselected subjects with pulmonary hypertension
Published in Internal and emergency medicine (01-04-2017)“…In patients with systemic sclerosis, a ratio between forced vital capacity (FVC) and diffusing capacity of carbon monoxide (DLCO, FCV%/DLCO%) >1.5 might be a…”
Get full text
Journal Article -
19
Adherence to GOLD guidelines in real-life COPD management in the Puglia region of Italy
Published in International journal of chronic obstructive pulmonary disease (01-01-2018)“…Background: COPD is a disease associated with significant economic burden. It was reported that Global initiative for chronic Obstructive Lung Disease (GOLD)…”
Get full text
Journal Article -
20
Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm3: A Post Hoc Analysis from the ANANKE Study
Published in Journal of asthma and allergy (01-01-2022)“…Purpose: Benralizumab effectively reduces severe eosinophilic asthma (SEA) exacerbations in patients with a wide range of baseline blood eosinophil count…”
Get full text
Journal Article